Poll

How do you manage patients with refractory OAB?

Usually refer to another urologist for InterStim
Usually refer to another urologist for PTNS
Usually refer to another urologist for onabotulinumA (Botox)
Usually manage myself
Other

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Post-RP incontinence: Low procedure rates examined
Roger Dmochowski, MD, on quality-of-life outcomes with the Revi System
Roger Dmochowski, MD, on quality-of-life outcomes with the Revi System
Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Data link incontinence severity to post-radical prostatectomy care
Shot of a doctor showing a patient some information on a digital tablet | Image Credit | © bongkarn - stock.adobe.com
OnabotA for OAB: Enhancing comfort and ensuring adherence
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Considerations for patient follow-up after onabotA administration
Administering onabotA: Improving patient comfort and easing anxiety
Administering onabotA: Improving patient comfort and easing anxiety
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © - bongkarn - stock.adobe.com
Experts discuss expanding use of vibegron for OAB
Related Content
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
July 9th 2025

Leva System adds Mayo Clinic overactive bladder content

Benjamin P. Saylor Hannah Clarke
Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Regulatory recap: FDA approvals in urology from the first half of 2025
July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke
Take a look through all the regulatory milestones in urology from the first half of the 2025.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
FDA updates in urology: June 2025
July 1st 2025

FDA updates in urology: June 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from June 2025.
Howard B. Goldman, MD, FACS
June 23rd 2025

The future of OAB treatment: Emerging nerve targets and AI may guide therapy

Howard B. Goldman, MD
Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.
© 2025 MJH Life Sciences

All rights reserved.